Joshua Field is an Oncology physician affiliated with Medical College of Wisconsin. OpenAlex indexes 166 publications with 3,331 citations (h-index 32); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9200 W Wisconsin Ave
Division Of Neoplastic Diseases
Milwaukee, WI 532263522
Telephone
414-805-6800Provider last certified this registry record 1 Oct 2020.
Clinical trials
- Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia
Sponsor: Vanderbilt University Medical Center
- Microvascular Blood Flow in Sickle Cell Anemia
Sponsor: Versiti Blood Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Chiesi USA, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
62.9%Opioid Agonist48.8%Oxycodone Hcl70%Oxycontin13%Methadone Hcl10%Morphine Sulfate4%Morphine Sulfate Er4%Part D<11 patientsPartial Opioid Agonist9.8%Buprenorphine-Naloxone100%Part D<11 patients+ 3 more classes in this area
Blood & clotting
24.7%Factor Xa inhibitor17.5%Eliquis71%Xarelto29%Part D≥51 patientsVitamin K antagonist4.3%Warfarin Sodium100%Part D≥15 patients+ 1 more class in this area
Cancer & immunology
10.1%Antimetabolite7.8%Hydroxyurea100%Part D≥40 patientsKinase inhibitor1.5%Jakafi100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease
Journal of Clinical Oncology
2023 - Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study
American Journal of Hematology
2022 - Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department
Annals of Internal Medicine
2021 - Identifying Clinical and Research Priorities in Sickle Cell Lung Disease. An Official American Thoracic Society Workshop Report
Annals of the American Thoracic Society
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Razelle Kurzrock, MD
Medical College of Wisconsin
Mary Horowitz, MD
Medical College of Wisconsin
Janet Rader, MD
Medical College of Wisconsin
Bruce Camitta, MD
Medical College of Wisconsin
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”